Monopar Therapeutics (MNPR): Total Assets
$140.72M
As of 2025-12-31
$134.98M
As of 2026-06-30
+119.9%
3-year compound annual growth
+52.8%
5-year compound annual growth
| Period ended | Total Assets | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $140.72M | +133.4% | 2026-03-27, Balance as of period end |
| 2024-12-31 | $60.29M | +720.8% | 2026-03-27, Balance as of period end |
| 2023-12-31 | $7.35M | -44.5% | 2025-03-31, Balance as of period end |
| 2022-12-31 | $13.23M | -35.5% | 2024-03-28, Balance as of period end |
| 2021-12-31 | $20.52M | +21.7% | 2023-03-23, Balance as of period end |
| 2020-12-31 | $16.87M | +26.3% | 2022-03-24, Balance as of period end |
| 2019-12-31 | $13.35M | +82.5% | 2021-03-25, Balance as of period end |
| 2018-12-31 | $7.32M | -26.3% | 2020-03-27, Balance as of period end |
| 2017-12-31 | $9.93M | +243.0% | 2019-02-26, Balance as of period end |
| 2016-12-31 | $2.90M | n/a | 2018-03-26, Balance as of period end |
Total Assets at similar companies
| Company | Year ended | Total Assets | Change YoY |
|---|---|---|---|
| Monopar Therapeutics (MNPR) | 2025-12-31 | $140.72M | +133.4% |
| Abbott Laboratories (ABT) | 2025-12-31 | $86.71B | +6.5% |
| Bristol Myers Squibb Co (BMY) | 2025-12-31 | $90.04B | -2.8% |
| TherapeuticsMD, Inc. (TXMD) | 2025-12-31 | $37.66M | -3.0% |
| Eli Lilly & Co (LLY) | 2025-12-31 | $112.48B | +42.9% |
| Pfizer Inc (PFE) | 2025-12-31 | $208.16B | -2.5% |
| Johnson & Johnson (JNJ) | 2025-12-28 | $199.21B | +10.6% |
| Nature's Sunshine Products Inc (NATR) | 2025-12-31 | $261.15M | +8.4% |
| Merck & Co., Inc. (MRK) | 2025-12-31 | $136.87B | +16.9% |
Compare MNPR, ABT, BMY, TXMD side by side · Screen every company in Pharmaceutical Preparations ↗